A
Aptinyx
Biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing transformative therapies for challenging disorders of the brain and nervous system. The company leverages its proprietary NMDA receptor modulator discovery platform to create novel therapeutic solutions for a range of central nervous system (CNS) disorders. Aptinyx's current pipeline includes multiple candidates in late-stage clinical development targeting conditions such as chronic pain and post-traumatic stress disorder (PTSD).
Aptinyx operates in the biopharmaceutical market, primarily serving patients suffering from CNS disorders. The business model is centered around the research and development of new drug candidates, which are then brought through clinical trials to demonstrate efficacy and safety. Revenue is generated through partnerships, licensing agreements, and eventually, the commercialization of successful therapies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2015
- Headquarters
- Evanston, United States
- Listing
- IPO 2018
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A12 investors entered at this stage
New Leaf Venture Partners
Latterell Venture Partners
Longitude Capital
Osage University Partners
Frazier Healthcare Partners
Beecken Petty O'Keefe & Company
Goudy Park Capital
Adams Street Partners
Bain Capital Life Sciences
Rock Springs Capital
Agent Capital
PFM Health Sciences
Series B and later1 investor entered at this stage
K2 HealthVentures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aptinyx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aptinyx on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.